Regulation - Research, Respiratory and Pulmonary

Filter

Popular Filters

FDA approves Bayer’s Adempas; firm accelerates drug candidates

FDA approves Bayer’s Adempas; firm accelerates drug candidates

09-10-2013

The US Food and Drug Administration late yesterday approved Adempas (riociguat), developed by German…

AdempasBayerCardio-vascularcopanlisibfinerenoneNorth AmericaOncologyPharmaceuticalRegulationResearchRespiratory and PulmonaryWomen's Health

The case for Insmed's CF drug candidate Arikace; analysts' views

05-07-2013

The 16% decline in US biotech firm Insmed's (Nasdaq CM: INSM) stock is an overreaction to results from…

ArikaceBiotechnologyFinancialInsmedRare diseasesRegulationResearchRespiratory and Pulmonary

Positive Ph III findings on ALK's new house dust mite allergy immunotherapy; EU filing expected in 2014

20-06-2013

Denmark-based allergy specialist ALK Abello (ALKB: DC) has announced positive outcome of the first of…

ALK AbelloImmunologicalsPharmaceuticalRegulationResearchRespiratory and Pulmonary

Genentech Ph III study of omalizumab shows promise in CIU

25-02-2013

Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

Novartis/Vectura's QVA149 is filed as a treatment for COPD in Europe; Certican EU approval

26-10-2012

The UK's Vectura Group (LSE: VEC) confirmed that its partner, Swiss drug giant Novartis (NOVN: VX) has…

CerticanEuropeFinancialImmunologicalsNovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonaryVectura

Actelion files for US approval of Opsumit for PAH

23-10-2012

Europe's largest biotech company Actelion (SIX: ATLN) said yesterday that it has submitted a New Drug…

ActelionBiotechnologymacitentanNorth AmericaOpsumitRegulationResearchRespiratory and Pulmonary

Novartis set to file QVA149 filing in EU and Japan by end of year

31-08-2012

Swiss drug major Novartis announced yesterday that the fifth QVA149 (indacaterol maleate/glycopyrronium…

NovartisPharmaceuticalQVA149RegulationResearchRespiratory and PulmonarySeebri BreezhalerVectura

GSK completes LAMA/LABA Ph III program; readies for global filings

28-08-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) say they have completed…

GlaxoSmithKlinePharmaceuticalRegulationResearchRespiratory and PulmonaryTheravanceumeclidiniumvilanterol

SkyePharma partner Kyorin completes Japanese Flutiform clinical program

26-06-2012

UK drug delivery specialist SkyePharma (LSE: SKP) saw its shares leap nearly 11% to £76.50 last…

Asia-PacificFlutiformKyorin PharmaceuticalsPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Strong results for Bayer's Xarelto in treating pulmonary blood clots

27-03-2012

German drugs and crops sciences group Bayer (BAY: DE), and partner Janssen, part of US health care major…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalRegulationResearchRespiratory and PulmonaryXarelto

GSK and Theravance to file COPD/asthma drug

10-01-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and partner USA-based Theravance (Nasdaq: THRX), in which…

GlaxoSmithKlinePharmaceuticalRegulationRelovairResearchRespiratory and PulmonaryTheravance

Skyepharma updates on Exparel, Flutiform and financial position

14-11-2011

UK drug developer SkyePharma (LSE: SKP) yesterday issued an update on its R&D pipeline and provided an…

Anti-Arthritics/RheumaticsExparelFinancialFlutiformLodotraPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Vectura shares fall as partner Novartis reports US delay for lung cancer drug

26-10-2011

Shares of UK-based Vectura (LSE: VEC) tumbled 22% at 66 pence on Tuesday, after the company revealed…

NovartisPharmaceuticalRegulationResearchRespiratory and PulmonarySeebriVectura

Insmed tumbles as FDA continues hold on Ph III Arikace trial

11-10-2011

US biopharmaceutical company Insmed (Nasdaq CM: INSM) saw its share price plunge 32% to $2.95 in morning…

ArikaceBiotechnologyInsmedNorth AmericaPharmaceuticalRegulationResearchRespiratory and Pulmonary

United Thera’s oral PAH drug treprostinil fails in Ph III study

26-08-2011

US biotech firm United Therapeutics (Nasdaq: UTHR) says that preliminary results from its FREEDOM-C(2)…

BiotechnologyRegulationResearchRespiratory and PulmonaryTreprostinilUnited Therapeutics

Back to top